Sunosi is owned by Jazz.
Sunosi contains Solriamfetol Hydrochloride.
Sunosi has a total of 9 drug patents out of which 0 drug patents have expired.
Sunosi was authorised for market use on 17 June, 2019.
Sunosi is available in tablet;oral dosage forms.
Sunosi can be used as to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa), to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily, treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment, treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily.
Drug patent challenges can be filed against Sunosi from June, 2023.
The generics of Sunosi are possible to be released after 19 March, 2040.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8877806 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(3 years from now) | |
US9604917 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(3 years from now) | |
US10351517 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(3 years from now) | |
US8440715 | JAZZ | Treatment of sleep-wake disorders |
Aug, 2027
(4 years from now) | |
US10512609 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
US10195151 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
US10912754 | JAZZ | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(15 years from now) | |
US10959976 | JAZZ | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(15 years from now) | |
US10940133 | JAZZ | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment
Dosage: TABLET;ORAL
Sunosi is owned by Axsome Malta.
Sunosi contains Solriamfetol Hydrochloride.
Sunosi has a total of 1 drug patent out of which 0 drug patents have expired.
Sunosi was authorised for market use on 17 June, 2019.
Sunosi is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Sunosi from June, 2023.
The generics of Sunosi are possible to be released after 05 November, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: NA
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic